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Objective. To analyze the prognostic value of demo-
graphic, clinical, and therapeutic factors and laboratory
biomarkers and to assess their role in predicting uveitis
occurrence in patients with juvenile idiopathic arthritis
(JIA).
Methods. Patients with JIA were enrolled within
the first year after JIA diagnosis. Demographic and clini-
cal parameters were documented. Serum samples were
collected at study enrollment, at 3-month follow-up visits
within the first year, and then every 6 months. A multi-
variable Cox regression analysis was performed to evalu-
ate the impact of demographic, clinical, laboratory, and
therapeutic parameters on uveitis onset.
Results. We included 954 JIA patients (67.2%
female, 54.2% antinuclear antibody [ANA] positive, mean
 SD age at onset 7.1  4.6 years). Uveitis occurred in 133
patients (observation period 44.5 months). Young age at
JIA onset and ANA positivity were significantly associated
with the onset of uveitis (both P < 0.001). Treatment of
arthritis with methotrexate alone (hazard ratio [HR] 0.18
[95% confidence interval (95% CI) 0.12–0.29], P < 0.001)
or combined with etanercept (HR 0.10 [95% CI 0.04–0.23],
P < 0.001) or adalimumab (HR 0.09 [95% CI 0.01–0.61], P
= 0.014) reduced the risk of uveitis onset and the occur-
rence of uveitis-related complications. Predictors of uveitis
onset included elevated erythrocyte sedimentation rate at
baseline (HR 2.36 [95% CI 1.38–4.02], P = 0.002) and con-
tinuing moderate or high disease activity during follow-up
as measured by the 10-joint clinical Juvenile Arthritis Dis-
ease Activity Score (HR 4.30 [95% CI 2.51–7.37], P <
0.001). Additionally, S100A12 levels ≥250 ng/ml at baseline
were significantly associated with the risk of uveitis (HR
2.10 [95% CI 1.15–3.85], P = 0.016).
Conclusion. Apart from demographic risk factors
and treatment modalities, JIA disease activity scores and
laboratory biomarkers could be used to better define the
group of JIA patients at high risk of uveitis onset.
Juvenile idiopathic arthritis (JIA) is a heteroge-
neous group of diseases with arthritis onset before age 16
years. In ~9–13% of patients with JIA, uveitis becomes
manifest (1,2) and may lead to vision-threatening compli-
cations (3–5). Previous studies have identified different
risk factors for uveitis onset in JIA, namely, oligoarthritis
subtype, young age at arthritis onset, short duration of JIA
disease, and antinuclear antibody (ANA) positivity (6–8).
Uveitis occurrence is subject to geographic variations, with
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a higher rate in northern countries (e.g., Scandinavian
countries and Germany) and a lower frequency in eastern
and southern Asia (1,2,7). Furthermore, disease-modifying
antirheumatic drug (DMARD) treatment in JIA patients
may reduce the risk of uveitis onset, especially if instituted
early in the course of disease (9).
Different molecular biomarkers have recently
been investigated in arthritis patients in order to detect
residual inflammation and the risk of arthritis flares after
remission or after discontinuing treatment. A laboratory
biomarker that offers the potential of a reliable outcome
measure would be desirable for clinicians. An elevated
erythrocyte sedimentation rate (ESR) may indicate activ-
ity of an autoimmune disease. Indeed, previous studies
indicated an elevated risk of uveitis in JIA patients with
an elevated ESR (10–13), while no such correlation was
found in others (2,14). For other factors (e.g., C-reactive
protein [CRP]), no correlation with uveitis risk in JIA has
been found previously (10,12,13).
A new and promising approach is the determina-
tion of serum levels of S100 proteins, a group of damage-
associated molecular pattern molecules expressed in cells
of myeloid origin. S100 molecules mediate inflammatory
responses of the innate immune system and recruit inflam-
matory cells to the site of tissue damage (15). S100A8/A9
complexes (myeloid-related protein 8 [MRP-8]/MRP-14;
calprotectin) and S100A12 are calcium-binding proteins
that mediate inflammatory responses through the receptor
for advanced glycation end products and Toll-like recep-
tors, after release from activated or necrotic cells (16). It
has been shown that the MRPs S100A8 and S100A9 play
a distinct role in neutrophil and monocyte activation (17).
Analysis of these factors represents a promising tool for
monitoring inflammation in JIA patients and in other
(auto)inflammatory or autoimmune diseases (15,17–20).
Indeed, serum levels of S100A8 and S100A9 have been
shown to be useful for assessing the risk of further arthritis
flares after methotrexate (MTX) withdrawal in JIA (21).
Increased levels of S100A12 reflect neutrophil activation
(15,20) and—similar to S100A8/A9—are useful for detecting
low-level inflammation and predicting risk of relapses in
JIA (19,22). Although it has been shown that elevated
S100 serum levels reflect intraocular inflammation in JIA
(23), no data are available about the impact of S100
serum protein levels on uveitis occurrence, outcome, and
response to treatment. This would be a desirable monitor-
ing instrument and prospective marker for assessing JIA
patients at risk of uveitis manifestations or of a severe
course of this ocular disease.
The aim of this study was to analyze the role of
demographic factors, DMARD treatment, and laboratory
biomarkers—particularly S100A12—to predict occurrence
of uveitis in the prospective, controlled Inception Cohort
of Newly diagnosed patients with Juvenile Idiopathic
Arthritis (ICON-JIA).
PATIENTS AND METHODS
Patients and controls. The ICON-JIA study is a prospec-
tive, controlled, observational, multicenter study. We included
patients with JIA defined according to the International League
of Associations for Rheumatology classification (24) and with
recent disease onset (diagnosis <12 months before enrollment).
Eleven pediatric rheumatology centers in Germany are participat-
ing in this study (during the recruitment period, the units reached
>33% of patients with incident JIA expected in the population in
Germany). For more details on the ICON-JIA cohort study, see
Sengler et al (25). For this analysis, the observation period ended
at the last follow-up visit in patients without uveitis and on the
date of occurrence of uveitis in patients who developed uveitis
during the follow-up period. The loss to follow-up was low, with
an annual dropout rate of 3.4% over the study period.
Data and blood sample collection. Patients were exam-
ined by a pediatric rheumatologist and an ophthalmologist quar-
terly during the first year and every 6 months thereafter. Various
demographic and clinical data (e.g., count of joints with active
disease [range 0–70] and global assessment of disease activity on
a Numerical Rating Scale [21-point; 0–10]) and medical and
family history were collected with standardized case report forms
and questionnaires. JIA disease activity was evaluated using the
10-joint clinical Juvenile Arthritis Disease Activity Score (cJA-
DAS-10). The cJADAS-10 (range 0–30) includes the physician’s
global assessment of disease activity, the parents’ global assess-
ment of overall well-being, and the number of joints with active
disease (maximum of 10). The cJADAS-10 thresholds proposed
by Consolaro and Ravelli (26) were applied to define disease
activity states for oligoarticular and polyarticular JIA (≤1 = inac-
tive; >1–≤1.5 and >1–≤2.5 = minimal; >1.5–≤4 and >2.5–≤8.5 =
moderate; >4 and >8.5 = high, respectively).
At enrollment and at the follow-up visits every 3 months
within the first year and every 6 months thereafter, standard
inflammation markers (e.g., ESR, CRP level, and platelet count)
and S100 proteins, cytokines, and chemokines were measured
from serum samples. A double-sandwich enzyme-linked immu-
nosorbent assay system was used to determine S100A12 levels.
The ESR cutoff of ≥20 mm/hour was applied to define elevated
ESR levels in accordance with the definition of the JADAS-10
(27). The readers of the laboratory assays were blinded with
regard to the diagnosis. Additionally, immunoglobulins, autoan-
tibodies (rheumatoid factor [RF] and ANAs), and HLA–B27
status were determined at inclusion. Ophthalmologic screening
was performed according to current screening recommendations
(2); findings were directly recorded with standardized question-
naires by the ophthalmologist who cared for the patient, and
uveitis was classified according to the Standardization of Uveitis
Nomenclature Working Group criteria (28).
Statistical analysis. Descriptive data were reported as
the mean  SD or the median and interquartile range for con-
tinuously distributed variables, as appropriate. Distributions of
categorical variables were described by absolute and relative
frequencies. A multivariable Cox regression analysis was per-
formed to evaluate the associations of demographic, clinical
(JADAS-10 score, etc.), laboratory (S100A12 and ESR), and
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therapeutic parameters with uveitis onset. These analyses also
included time-dependent covariates (change in disease severity
across time and change in therapy) to model the change in the
underlying risk of incidence of uveitis. A clinically meaningful
threshold of 250 ng/ml for S100A12 levels was determined at
the maximum of the Youden index based on receiver operating
characteristic curve analysis (29). Missing values in categorical
predictor variables were modeled by an additional category.
Hazard ratios (HRs) are reported with 95% confidence inter-
vals (95% CIs). P values less than 0.05 were considered signifi-
cant. All statistical analyses were conducted using SAS
software, version 9.3 (SAS Institute).
Ethics committee approval. The study was approved
by the ethics committee of the Charite Universit€atsmedizin
Berlin. Subjects’ consent was obtained according to the Dec-
laration of Helsinki, and the design of the work conforms to
the standards currently applied in Germany.
RESULTS
Demographic data. A total of 954 JIA patients
were included in the study (67.2% female, 54.2% ANA
positive, mean  SD age at onset 7.1  4.6 years)
(Table 1). The mean  SD follow-up time was 44.5 
22.8 months. Uveitis occurred in 133 patients (13.9%)
during the observation period. Uveitis developed in 4 of
these patients (0.4% of all JIA patients; 3.0% of all with
uveitis) before the first JIA symptoms became manifest,
with a mean  SD duration of 11.0  5.6 months between
uveitis onset and first JIA symptoms. New uveitis onset
was recorded for 65 (6.8% of all JIA patients; 48.9% of
all with uveitis), 24 (2.5% of all JIA patients; 18.0% of all
with uveitis), and 19 (2.0% of all JIA patients; 14.3% of
all with uveitis) patients in the first, second, and third
year, respectively, after first JIA symptoms. In 52 patients
(5.5% of all JIA patients; 39.1% of all with uveitis), uveitis
occurred after first JIA symptoms became manifest and
before ICON-JIA study enrollment. A total of 21 patients
(2.2% of all JIA patients; 15.8% of all with uveitis) devel-
oped uveitis after 3 years or later after JIA onset (see
Supplementary Figure 1, available on the Arthritis &
Rheumatology web site at http://onlinelibrary.wiley.com/
doi/10.1002/art.40544/abstract).
Established risk factors for uveitis. The estab-
lished risk factors for uveitis onset were analyzed in the
total sample of 954 patients. Female sex, young age at
JIA onset, the JIA category of oligoarthritis, and ANA
positivity were significantly associated with the onset of
uveitis in univariate analyses (Table 2). Moreover, ANA
positivity (HR 2.79 [95% CI 1.66–4.69], P < 0.001) and
age <3 years at JIA onset (HR 2.8 [95% CI 1.9–4.0], P <
0.001) were also significantly associated with risk of uve-
itis in multivariable analysis. The multivariable model
had good power to predict the risk of uveitis (Harrel’s
C = 0.77).
Impact of treatment on uveitis onset. The influ-
ence of treatment on the risk of uveitis was analyzed in
898 patients (the sample excluded patients with uveitis
onset before enrollment in the ICON-JIA study [see
Table 1]). Treatment of arthritis with MTX significantly
reduced the risk of subsequent uveitis onset (HR 0.16
[95% CI 0.11–0.24], P < 0.001). This effect was also statis-
tically significant after adjustment for established uveitis
risk factors (HR 0.14 [95% CI 0.09–0.21], P < 0.001).
Table 1. Demographic and clinical data on the JIA patients at
enrollment in the ICON-JIA study*
Total
sample
Sample excluding
patients with uveitis
before enrollment in
the ICON-JIA study
(n = 954)† (n = 898)‡
Female 641 (67.2) 601 (66.9)
Age at symptom onset,
mean  SD years
7.1  4.6 7.3  4.7
Time from symptom onset
to diagnosis,
median (IQR) months
3.0 (1.0–7.0) 3.0 (1.0–7.0)
Time from diagnosis to
enrollment,
median (IQR) months
1.6 (0.4–4.4) 1.5 (0.4–4.2)
JIA category
Systemic arthritis 35 (3.7) 35 (3.9)
Oligoarthritis 445 (46.7) 410 (45.7)
Psoriatic arthritis 39 (4.1) 38 (4.2)
Enthesitis-related arthritis 100 (10.5) 94 (10.5)
RF-positive polyarthritis 15 (1.6) 15 (1.7)
RF-negative polyarthritis 252 (26.4) 242 (26.9)
Undifferentiated arthritis 68 (7.1) 64 (7.1)
cJADAS-10, mean  SD 9.8  6.2 9.9  6.3
Inactive disease 56 (6.1) 51 (5.9)
Minimal disease activity 24 (2.6) 22 (2.6)
Moderate disease activity 173 (18.9) 164 (19.0)
High disease activity 664 (72.4) 626 (72.5)
ANA positive§ 517 (54.2) 469 (52.2)
RF positive§ 31 (3.3) 31 (3.5)
HLA–B27 positive§ 146 (15.3) 139 (15.5)
ESR, mean  SD mm/hour¶ 22.8  21.7 22.7  21.9
S100A12, mean  SD ng/ml# 337.5  806.8 347.8  833.0
Uveitis 133 (13.9) 77 (8.6)
* Except where indicated otherwise, values are the number (%). JIA =
juvenile idiopathic arthritis; ICON-JIA = Inception Cohort of Newly
diagnosed patients with Juvenile Idiopathic Arthritis; IQR = interquartile
range; cJADAS-10 = 10-joint clinical Juvenile Arthritis Disease Activity
Score.
† Sample for the analysis of “classic” risk factors.
‡ Sample for the analysis of clinical parameters and biomarkers for
the risk of uveitis during follow-up.
§ Percentages refer to the total numbers of 954 and 898 patients in
the total sample and the sample excluding patients with uveitis before
enrollment, respectively. Test results were missing for antinuclear anti-
body (ANA) positivity (44 patients [4.6% of all patients]), rheumatoid
factor (RF) positivity (177 patients [18.6% of all patients]), and HLA–
B27 positivity (234 patients [24.5% of all patients]).
¶ Erythrocyte sedimentation rate (ESR) was reported in 794 and 744
patients, respectively.
# Measured in 529 and 494 patients in the total sample and the sam-
ple excluding patients with uveitis before enrollment, respectively.
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Patients receiving MTX monotherapy (HR 0.18 [95% CI
0.12–0.29], P < 0.001; n = 414) or MTX combined with
etanercept (HR 0.10 [95% CI 0.04–0.23], P < 0.001; n =
170) showed a reduced risk of uveitis onset. This effect
might rely mostly on the effect from MTX, as the uveitis
risk was not altered with etanercept monotherapy (HR
0.76 [95% CI 0.28–2.07], P = 0.589; n = 16). However, the
study might have been underpowered for the analysis of
Table 2. Risk of incident uveitis from onset of first JIA symptoms in the Inception Cohort of Newly diagnosed patients with Juvenile Idiopathic
Arthritis study (n = 954)*
Patients without
uveitis at
Patients with
uveitis at
Incidence of
uveitis at Univariate analysis Multivariable analysis§
follow-up follow-up follow-up
(n = 821) (n = 133) (n = 133)† HR (95% CI) P C‡ HR (95% CI) P
Female 542 (66.0) 99 (74.4) 99 (15.4) 1.50 (1.01–2.23) 0.048 0.55 0.97 (0.64–1.45) 0.865
Age at JIA symptom onset,
mean  SD years
7.7  4.6 3.8  3.0 – 0.79 (0.74–0.84) <0.001 0.75 0.82 (0.78–0.88) <0.001
JIA category
Oligoarthritis 360 (43.9) 85 (63.9) 85 (19.1) 2.16 (1.51–3.10)¶ <0.001 0.59 1.36 (0.94–1.96)¶ 0.104
RF-negative polyarthritis 219 (26.7) 33 (24.8) 33 (13.1)
RF-positive polyarthritis 15 (1.8) 0 (0.0) 0 (0.0)
Psoriatic arthritis 37 (4.5) 2 (1.5) 2 (5.1)
Enthesitis-related arthritis 92 (11.2) 8 (6.0) 8 (8.0)
Systemic arthritis 35 (4.3) 0 (0.0) 0 (0.0)
Undifferentiated arthritis 63 (7.7) 5 (3.8) 5 (7.4)
ANA positive, no. (% tested) 404 (49.2) 113 (85.0) 113 (21.9) 5.00 (3.03–8.23) <0.001 0.66 2.79 (1.66–4.69) <0.001
RF positive, no. (% tested) 31 (3.8) 0 (0.0) 0 (0.0) – – – – –
HLA–B27 positive, no.
(% tested)
135 (16.4) 11 (8.3) 11 (7.5) 0.52 (0.28–0.97) 0.040 0.54 0.80 (0.42–1.50) 0.481
* Except where indicated otherwise, values are the number (%). HR = hazard ratio; 95% CI = 95% confidence interval; RF = rheumatoid factor.
† Incidence of uveitis within a group (row percentage).
‡ Harrel’s C, a measure to evaluate the predictive power of parameters to predict the risk of uveitis ranging between 0.5 and 1 (0.5 = prediction
by chance, 1 = perfect prediction). The multivariable model had good power to predict the risk of uveitis (Harrel’s C = 0.77).
§ Predictors in the multivariable model were female sex, age at first symptoms of juvenile idiopathic arthritis (JIA), oligoarthritis (versus all other
JIA categories), antinuclear antibody (ANA) positivity, and HLA–B27 positivity.
¶ The reference is all other categories of JIA.
Table 3. Univariate and multivariable analysis of the impact of cJADAS-10, ESR, and S100A12 levels on the
incidence of uveitis in the Inception Cohort of Newly diagnosed patients with Juvenile Idiopathic Arthritis
study, at enrollment and during follow-up*
Univariate analysis Multivariable analysis†
HR (95% CI) P HR (95% CI) P
Parameters at enrollment
(visits with available measurements)
cJADAS-10 (882)‡ 1.00 (0.96–1.04) 0.867 1.02 (0.98–1.07) 0.308
Moderate or high disease activity 1.56 (0.57–4.28) 0.390 1.72 (0.62–4.78) 0.301
ESR (770)‡ 1.02 (1.01–1.03) <0.001 1.02 (1.01–1.03) <0.001
ESR ≥20 mm/hour 2.98 (1.78–5.00) <0.001 2.36 (1.38–4.02) 0.002
S100A12 (517)‡ 1.40 (1.14–1.72) 0.001 1.50 (1.15–1.96) 0.003
S100A12 ≥250 ng/ml 2.66 (1.47–4.82) 0.001 2.10 (1.15–3.85) 0.016
Time-varying parameters at follow-up
(visits with available measurements)
cJADAS-10 (6,104)‡ 1.10 (1.05–1.15) <0.001 1.17 (1.11–1.23) <0.001
Moderate or high disease activity 3.41 (2.01–5.77) <0.001 4.30 (2.51–7.37) <0.001
ESR (4,329)‡ 1.03 (1.01–1.04) <0.001 1.03 (1.01–1.05) 0.001
ESR ≥20 mm/hour 2.57 (1.48–4.46) 0.001 2.44 (1.37–4.36) 0.003
S100A12 (1,901)‡ 1.18 (0.81–1.72) 0.379 1.21 (0.81–1.82) 0.351
S100A12 ≥250 ng/ml 1.45 (0.57–3.70) 0.438 1.54 (0.60–3.99) 0.372
* 95% CI = 95% confidence interval.
† Adjusted for age at disease onset, oligoarthritis, antinuclear antibody positivity, and treatment with
methotrexate and biologic disease-modifying antirheumatic drugs.
‡ Hazard ratio (HR) for the increase by 1 unit in the 10-joint clinical Juvenile Arthritis Disease Activity Score (cJA-
DAS-10) and the erythrocyte sedimentation rate (ESR), and for the increase by 50 units in the S100A12 level.
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etanercept monotherapy. Treatment with adalimumab as
monotherapy (n = 17) or in combination with MTX (n =
55) was also associated with a lower risk of uveitis onset
(HR 0.09 [95% CI 0.01–0.61], P = 0.014; n = 72).
Laboratory and clinical biomarkers as risk factors
for uveitis onset. ESRs (in mm/hour) and S100A12 levels
(in ng/ml) were available at enrollment for 770 and 517
patients, respectively. A total of 216 patients (42%) with
S100A12 measurement at baseline started DMARD treat-
ment prior to the first S100A12 measurement (median
duration of 1.5 months between start of DMARD treat-
ment and S100A12 measurement at baseline). During the
follow-up period, ESRs and S100A12 levels could be ana-
lyzed for 4,329 and 1,901 visits, respectively. Patients with-
out uveitis during the observation period had a mean SD
ESR of 21.8  21.3 mm/hour at enrollment compared to
32.5  26.4 mm/hour in patients with uveitis manifestations
(see Supplementary Figure 2A, available at http://online
library.wiley.com/doi/10.1002/art.40544/abstract). Similarly,
mean  SD S100A12 levels were 338  849 ng/ml in
patients without uveitis at enrollment and 434  681 ng/ml
in patients with uveitis at follow-up (see Supplementary
Figure 2B). Both ESR and S100A12 were significantly
associated with risk of uveitis onset in univariate and multi-
variable analyses (Table 3). Elevated S100A12 levels (≥250
ng/ml) during the JIA disease course did not show a signifi-
cant association with the risk of uveitis at follow-up (HR
1.45 [95% CI 0.57–3.70], P = 0.438) (Table 3).
Importantly, clinically active arthritis—in fact,
moderate or high active disease state as measured by the
cJADAS-10—during the follow-up period significantly pre-
dicted subsequent uveitis onset (HR 3.41 [95% CI 2.01–
5.77], P < 0.001). Patients with an elevated ESR (≥20 mm/
hour) at the visit before uveitis onset were at higher risk of
developing uveitis (HR 2.44 [95% CI 1.37–4.36], P =
0.003) (Table 3 and Figure 1), after adjustment for the
established risk factors and arthritis treatment. In a multi-
variable analysis, moderate or high active disease state as
measured by the cJADAS-10 and elevated ESRs was also
significantly associated with uveitis onset (Table 3).
Identifying children at risk of uveitis onset is espe-
cially important for JIA subgroups in which (silent)
chronic anterior uveitis may occur, as uveitis may go unno-
ticed for a longer time period in these children compared
to children in other JIA subgroups (e.g., enthesitis-related
arthritis [ERA], with acute anterior uveitis). Therefore, we
Figure 1. Relative risk of uveitis onset based on age at onset of juvenile idiopathic arthritis (JIA), antinuclear antibody (ANA) positivity, and
erythrocyte sedimentation rate (ESR) at follow-up, adjusted for the 10-joint clinical Juvenile Arthritis Disease Activity Score and treatment with
methotrexate (MTX) and MTX/biologic disease-modifying antirheumatic drugs.
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performed a subgroup analysis for those children who
typically may develop chronic anterior uveitis (i.e., oligo-
arthritis, RF-negative polyarthritis, psoriatic arthritis, and
undifferentiated arthritis) (see Supplementary Tables 1
and 2, available at http://onlinelibrary.wiley.com/doi/10.
1002/art.40544/abstract). The risk factors for uveitis mani-
festations (Supplementary Table 1) and the predictive value
of ESR and S100A12 (Supplementary Table 2) in this sub-
group were similar to those in the whole JIA cohort in the
ICON-JIA study, without any remarkable differences
(Tables 2 and 3, respectively). The subgroup analysis for
children with ERA, who may typically develop acute ante-
rior uveitis instead of chronic anterior uveitis, was under-
powered (n = 8 patients with uveitis) due to a low number
of uveitis events or even none in the individual categories of
the risk factors.
Clinical characteristics at first uveitis documenta-
tion. A detailed characterization of uveitis at initial docu-
mentation was available for 116 patients (87%), providing
information on 162 affected eyes. At first uveitis documenta-
tion, bilateral uveitis was seen in 47 patients (40.5%), and
an anterior chamber cell grade ≤2+ was found in 92% of
patients (0.5+ in 20.7%, 1+ in 27.6%, and 2+ in 28.7% of
patients). Uveitis-related complications were present in
28.7% of patients at first uveitis documentation (mainly pos-
terior synechiae in 20.9% of patients and cataracts in 7.8%).
Patients with and those without uveitis-related
complications at first uveitis documentation did not dif-
fer remarkably with regard to sex, JIA category, ANA
positivity, and age at disease onset (Table 4). JIA
patients being treated with DMARDs, specifically MTX
or biologic DMARDs before uveitis onset, had slightly
fewer uveitis-related complications at first uveitis docu-
mentation (Table 4). In the exploratory analysis of
patients with uveitis onset after ICON-JIA study enroll-
ment, parameters such as the cJADAS-10, ESR, and
S100A12 level were analyzed with regard to the pres-
ence of secondary complications of uveitis at first docu-
mentation of disease (Table 5).
DISCUSSION
As uveitis manifestations in patients with JIA are
often initially asymptomatic and may lead to irreversible
vision impairment, identifying children at risk of uveitis is
crucial. Current screening guidelines, based on JIA cate-
gory, ANA positivity/negativity, age at JIA onset, and JIA
disease duration, recommend screening intervals between
3 and 12 months (2,30). Using additional demographic,
clinical, and laboratory biomarkers to even better define
patients at risk of uveitis onset would be highly desirable.
Furthermore, early DMARD treatment might be consid-
ered for the high-risk group with high rates of uveitis
onset and ocular complications if the number needed to
treat as well as a better outcome for such an approach
could be justified by confirmed evidence.
In this study cohort, uveitis occurred in 13.9%
of children with JIA, which is consistent with previous
Table 4. Presence of uveitis-related ocular complications at initial
uveitis documentation (univariate analyses)*
No uveitis-related
complications
Any uveitis-related
complications
(n = 82) (n = 33)
Female sex 64 (78.1) 24 (72.7)
Oligoarticular JIA 54 (65.9) 21 (63.6)
ANA positivity 69 (84.2) 30 (90.9)
HLA–B27 positivity 5 (6.1) 3 (9.1)
Age at JIA onset,
mean  SD years
3.4  2.7 4.6  3.3
Age at JIA onset ≤3 years 50 (61.0) 14 (42.4)
JIA disease duration,
mean  SD months
17.4  16.9 6.0  23.1
Uveitis onset after JIA onset 1 (1.2) 3 (9.1)
Previous therapy
No DMARDs 56 (68.3) 30 (90.9)
Methotrexate 23 (28.1) 3 (9.1)
Etanercept 6 (7.3) 2 (6.1)
Adalimumab 1 (1.2) 0 (0.0)
* Except where indicated otherwise, values are the number (%). JIA =
juvenile idiopathic arthritis; ANA = antinuclear antibody; DMARDs =
disease-modifying antirheumatic drugs.
Table 5. Presence of uveitis-related ocular complications at initial
uveitis documentation for patients with uveitis onset after enrollment
in the Inception Cohort of Newly diagnosed patients with Juvenile
Idiopathic Arthritis study*
No uveitis-related
complications
Any uveitis-related
complications
(n = 54) (n = 8)
Parameters at enrollment
cJADAS-10, mean  SD 9.57  5.05 9.88  8.00
Moderate or high disease
activity
51 (94.4) 7 (87.5)
ESR, mean  SD
mm/hour
32.27  22.72 37.03  27.61
ESR ≥20 mm/hour 37 (68.5) 6 (75.0)
S100A12, mean  SD
ng/ml
497.53  777.64 412.80  131.26
S100A12 ≥250 ng/ml 19 (51.4) 4 (80.0)
Parameters at follow-up
cJADAS-10, mean  SD 4.95  4.27 3.00  2.98
Moderate or high disease
activity
32 (65.3) 3 (60.0)
ESR, mean  SD
mm/hour
20.57  15.37 13.60  7.79
ESR ≥20 mm/hour 19 (38.0) 1 (20.0)
S100A12, mean  SD
ng/ml
204.15  147.50 81.00 (–)
S100A12 ≥250 ng/ml 6 (31.6) 0 (0.0)
* Except where indicated otherwise, values are the number (%).
cJADAS-10 = 10-joint clinical Juvenile Arthritis Disease Activity
Score; ESR = erythrocyte sedimentation rate.
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publications reporting an overall prevalence of uveitis in
JIA of ~9–13% (1,7,31,32); however, higher rates from
Nordic countries of up to 20.5% have also been reported
(14). In this large, prospective, multicenter study, demo-
graphic risk factors, namely, young age at JIA onset, JIA
category, and ANA positivity, were significantly associ-
ated with the risk of uveitis onset. These findings corrob-
orate the results of previous studies (2,9,14,33). In our
study, female sex was found to be a significant risk factor
for uveitis in the univariate analysis but not in the multi-
variable analysis. This corresponds to the results from
other cohorts, in which sex was not found to be an inde-
pendent risk factor (1,2,14,34,35). This may be explained
by the predominance of females among those with onset
of oligoarticular JIA at young age and by the higher per-
centage of ANA-positive females (35). A lower risk of
uveitis onset within this group of JIA patients with inter-
mediate follow-up duration was found for HLA–B27–
positive children; however, this was significant only in
the univariate analysis. HLA–B27 positivity in uveitis
cases has been described previously, particularly in the
ERA subgroup, and uveitis occurrence might increase
with longer follow-up duration (2,36).
Children receiving conventional synthetic or bio-
logic DMARDs had a significantly lower risk of uveitis
onset in the current study, especially when receiving MTX
and/or adalimumab. Preliminary evidence for a protective
effect of MTX in JIA was found in a retrospective study
by Papadopoulou et al, with uveitis developing in 10.5%
of patients receiving MTX compared to 20.2% in those
not receiving MTX (odds ratio 0.46, P = 0.049) (37), while
such a role of immunosuppressive drugs was not clearly
confirmed in other studies (14,38). Ravelli et al (39)
recently reported an open-label trial comparing intraartic-
ular corticosteroids alone to intraarticular corticosteroids
plus MTX in JIA and found no significant difference in
new-onset uveitis between patients who received MTX
and those who did not (P = 0.4957). A protective effect of
DMARD treatment has also been suggested in one of our
previous studies, in which the uveitis prevalence de-
creased significantly between 2002 and 2013 from 13% to
11.6% in a national pediatric database, corresponding to
an increasing rate of both synthetic (mostly MTX) and
biologic DMARD use in the same time period (31).
Finally, in another prospective study by our group based
on a national database of 3,512 children with JIA in Ger-
many, we found that DMARD treatment significantly
reduced the risk of uveitis (for MTX alone, HR 0.63, P =
0.022; for tumor necrosis factor inhibitors, HR 0.56, P <
0.001; for a combination of the 2 medications, HR 0.10,
P < 0.001) (9). A maximum of 300 ICON-JIA study
patients may also have been included in our previous study,
which would represent 8.5% of the patient group exam-
ined. The different results for the potential protective
effect of MTX on uveitis manifestations might be
explained by differences in study populations, study designs
(particularly differences in ophthalmologic screening and
documentation, for example, frequent prospective uveitis
documentation only in the ICON-JIA study specifically
focusing on uveitis occurrence and course), follow-up peri-
ods, analysis power, and adjustment for other risk factors.
Furthermore, our study gave new insight into the
role of clinical activity scores and biomarkers (e.g., ESR
and S100A12) as prognostic markers for uveitis in JIA. In
4 previous studies, elevated ESR predicted uveitis mani-
festations (10–13), while this was only true for the ERA
subgroup of JIA in another study from a German cohort
(2). It may be speculated that a high ESR correlates with
the activity of autoimmune processes in JIA, potentially
under the influence of Treg cells (13). Furthermore, the
fact that high cJADAS scores indicate a higher risk of
uveitis onset supports this theory and also supports previ-
ous notions (9). In our study, an ESR ≥20 mm/hour at
enrollment indicated a significant risk of uveitis onset
(HR 2.36, P = 0.002). As ESR is tested routinely in chil-
dren with JIA, its use as a biomarker could easily be
implemented more systematically in clinical practice and
also in screening guidelines, as also suggested by
Haasnoot et al (13). When analyzing the absolute ESR
(instead of a cutoff of ≥20 mm/hour), only a modest HR
of 1.02 (P < 0.001) was found, which means that for each
1-mm elevation of ESR, the odds for the occurrence of
uveitis increase by 2%. Haasnoot et al (13) also found an
almost identical ratio (HR 1.016, P = 0.001).
Interestingly, S100A12 levels at enrollment pre-
dicted uveitis onset. In a pilot study, elevated S100A12
levels were found in the serum and aqueous humor of pa-
tients with autoimmune uveitis (23), indicating a promis-
ing potential for this biomarker. Previous data support
the use of S100A12 and S100A8/9 levels as a disease
activity marker for predicting disease relapse and to help
make therapeutic decisions in JIA (21,40,41). However, in
our study S100A12 levels during the course of JIA disease
did not show a significant relationship with the occurrence
of uveitis, which might be explained by the influence of
antiinflammatory treatment (23) (e.g., DMARDs), the
limited number of samples available for S100A12 analysis,
and high variations in levels. It must be considered that
the HR indicated a positive association of uveitis risk with
S100A12 levels during the course of disease, although
without statistical significance. This might have been
caused by low statistical power due to missing S100A12
measurements (compared to the numbers of available
ESR measurements).
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The ocular characteristics of eyes with uveitis at
study inclusion (n = 116 patients with complete ophthalmo-
logical documentation) were similar to those previously
reported (2,31,34). Occurrence of ocular complications
during the course of JIA-associated uveitis was described
in up to 90% of patients (32,42–47). At study inclusion,
uveitis-related complications were already found in 28.7%
of our patients, compared to 20–64% in previous reports
(2,34,48). Such differences may be explained by the intro-
duction of screening programs, the adoption of new JIA
treatment regimens in the past few decades, and early and
more aggressive treatment, particularly with biologic
DMARDs (31). In this regard, the inclusion of patients
within 1 year after JIA diagnosis (and not directly after JIA
or uveitis onset) has to be considered for our study. Simi-
larly, posterior synechiae and cataracts were the most com-
mon ocular complications at first presentation in previous
observations (2,34,48). In our study, risk factors for the
presence of early ocular uveitis-related complications were
young age at disease onset and absence of any DMARD
treatment. Interestingly, children treated with MTX, espe-
cially, demonstrated a significantly lower occurrence of
uveitis-related complications at study inclusion. Such a
relationship has also been found in previous studies (31).
The strengths of this study are its prospective multi-
center design with a clearly defined inception cohort (inclu-
sion of JIA patients within the first year of JIA diagnosis
only) that included a remarkably large number of patients
with documented ophthalmologic and pediatric rheumatic
conditions based on clearly defined outcome criteria.
Allowing the inclusion of children within 1 year and not
directly at JIA onset might represent a certain limitation of
this study; however, this made it possible to include this large
cohort of children. Although the majority of the patients
likely developed uveitis during the observation period, the
possibility cannot be excluded that more children could
develop uveitis after the mean follow-up period of 44.5
months. It must be mentioned that the ICON-JIA study did
not explicitly distinguish between insidious (chronic) and
acute-onset anterior uveitis. Due to this lack of differentia-
tion in the data collection, we performed a subgroup analy-
sis excluding all patients at risk of acute anterior uveitis (i.e.,
ERA, systemic arthritis, and RF-positive polyarthritis), and
we found no relevant differences compared to the analysis
of the whole JIA cohort (see Results).
It would be interesting to know the ANA titer and
its influence on uveitis risk. However, the ICON-JIA study
is an observational study that does not include the deter-
mination of ANAs in a central laboratory. The results of
the ANA determinations were only reported by the pedia-
tric rheumatologists, and these were carried out as part of
the diagnostic procedure at the routinely assigned local
laboratory. The cutoff for a positive titer of ANA may vary
among the ICON-JIA study center laboratories. There-
fore, only the ANA status (positive, negative, not deter-
mined) was recorded and not the ANA titer itself. The
cutoff of 250 ng/ml that we used to define elevated
S100A12 levels was estimated in our sample. This cutoff
has to be confirmed in other cohorts before it may be
applicable in general. Missing values in categorical predic-
tor variables were modeled by an additional category. A
complete case sensitivity analysis showed that the results
from the regression analyses were comparable to the
results reported herein. Because of this, the risk of biased
estimates may be limited (49). The analysis of uveitis-
related complications at first uveitis documentation had an
exploratory character because the study was not powered
for this analysis.
In conclusion, this prospective study has confirmed
demographic risk factors for uveitis in a large, prospective,
multicenter setting. Furthermore, it adds knowledge about
the predictive value of JIA disease activity scores and labo-
ratory biomarkers (e.g., ESRs and S100A12 levels) for the
risk of uveitis manifestations in JIA. Indeed, these parame-
ters are promising tools to better define the group of JIA
patients at high risk of uveitis onset. High S100A12 levels
and ESRs at JIA onset and high ESRs and high cJADAS-
10 scores during follow-up have been found to be signifi-
cant risk factors for uveitis manifestations.
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Clinical Images: Monoclonal gammopathy–associated scleromyxedema presenting as leonine facies
The patient, a 61-year-old man previously in good health, was referred to the scleroderma clinic for a 2-year history of slowly pro-
gressive cutaneous eruption involving the dorsal hands, extremities, and central area of the face. Physical examination revealed
nodular, erythematous, indurated lesions on the forehead and erythematous papular lesions on the nose with coalescence of firm
erythematous papulonodules, resulting in a leonine facies. On the dorsal hands, arms, and legs were numerous, shiny, firm, closely
set, slightly translucent papules measuring 1–2 mm with background erythema (A). Skin biopsy demonstrated a spindled fibroblas-
tic proliferation in the dermis with increased mucin and variable fibrosis (B). The clinical and histologic findings were diagnostic
of scleromyxedema. Scleromyxedema is a rare disorder of unknown pathogenesis characterized by a generalized lichenoid papular
cutaneous eruption and resulting in diffuse skin induration that may simulate scleroderma. Rarely, larger exophytic nodules, as
seen in this patient, may be present. The majority of scleromyxedema cases occur in association with a monoclonal gammopathy.
The patient was found to have an IgGk M protein spike. This patient did not exhibit any CRAB features (hypercalcemia, renal
insufficiency, anemia, and bone lesions), and evaluation including hematologic studies culminated in a diagnosis of IgGk
monogammopathy of unclear significance, with plans for ongoing observation. For his scleromyxedema, the patient received intra-
venous immunoglobulin (IVIG) at doses of up to 2 gm/kg/month (1), with significant improvement in the appearance of lesions
after 16 months (C). He continues to receive a maintenance dose of 1 gm/kg IVIG every 4 weeks.
Dr. Khanna’s work was supported by the NIH (National Institute of Arthritis and Musculoskeletal and Skin Diseases grants K24-
AR-063121 and R01-AR-070470).
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